UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of The  

Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): February 17, 2017 

CELGENE CORPORATION 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

 86 Morris Avenue, Summit, New Jersey 07901 

 (Address of principal executive offices) (Zip Code)  

Registrant’s telephone number, including area code: (908) 673-9000 

(Former name or former address, if changed since last report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

 ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

ITEM 8.01 OTHER EVENTS 

On February 17, 2017, Celgene Corporation issued a press release announcing certain results of its phase 3 SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release announcement. 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. 

Exhibit 99.1 – Press Release dated February 17, 2017 

SIGNATURES 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

EXHIBIT INDEX 

 Exhibit No.   Description 

 99.1   Press Release dated February 17, 2017